Daiichinkyo Co (FRA:D4S) 3-Year FCF Growth Rate : 55.60% (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co 3-Year FCF Growth Rate?

Daiichinkyo Co's Free Cash Flow per Share for the three months ended in Mar. 2024 was €-0.06.

During the past 12 months, Daiichinkyo Co's average Free Cash Flow per Share Growth Rate was 910.50% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was 55.60% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 35.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Daiichinkyo Co was 92.50% per year. The lowest was -48.70% per year. And the median was 17.30% per year.

Competitive Comparison of Daiichinkyo Co's 3-Year FCF Growth Rate

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Daiichinkyo Co's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's 3-Year FCF Growth Rate falls into.

Daiichinkyo Co 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Daiichinkyo Co (FRA:D4S) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Daiichinkyo Co 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Daiichinkyo Co (FRA:D4S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (FRA:D4S) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

DSNKY:USA DSKYF:USA 4568:Japan D4S:Germany

Address

3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426

Website

https://www.daiichisankyo.com

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co (FRA:D4S) Headlines

No Headlines